Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of RC1012 Injection for the Prevention of Relapse in AML Patients After Allogeneic Hematopoietic Stem Cell Transplantation

NCT05858814 is registered in ClinicalTrials.gov with Guangdong Ruishun Biotech Co., Ltd as lead sponsor.

NCT NCT05858814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05858814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of RC1012 Injection for the Prevention of Relapse in AML Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Guangdong Ruishun Biotech Co., Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 4, 2023
Completion date
June 24, 2026
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia